Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Music
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/1c/28/46/1c284650-49d4-6634-9910-779ba4c2e726/mza_1942905218397286773.jpg/600x600bb.jpg
Future Science Group
Taylor & Francis Group
302 episodes
6 days ago
Exploring biomarker testing in bioanalytical Contract Research Organizations
Show more...
Science
RSS
All content for Future Science Group is the property of Taylor & Francis Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Exploring biomarker testing in bioanalytical Contract Research Organizations
Show more...
Science
https://i1.sndcdn.com/artworks-jLGO1e5g1RLIsMVb-jSjx2g-t3000x3000.jpg
The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley
Future Science Group
21 minutes 35 seconds
10 months ago
The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley
In this episode, we sit down with Megan Cooley, Associate Director of Bioanalytical Services at ICON (KS, USA), to explore the cutting-edge world of antibody-drug conjugate (ADC) quantitation using high-resolution mass spectrometry (HRMS). Megan delves into the capabilities of Triple Quadrupole and Time-of-Flight mass spectrometry, offering her expert insights into whether HRMS is essential for ADC PK studies. We also tackle the challenges and limitations of HRMS in ADC quantitation and discuss the potential for AI to create more specific and stable ADCs. Finally, Megan highlights ICON’s extensive experience with large molecule applications and their innovative approach to supporting complex LC–MS analyses.
Future Science Group
Exploring biomarker testing in bioanalytical Contract Research Organizations